Ikarian Capital’s OnKure Therapeutics OKUR Stock Holding History

Ikarian Capital’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-108,260	Closed	-$1.73M	–	181
2023 Q4	$1.73M	Buy	+108,260	New	+$6.75M	0.16%	88

Other funds holding OKUR

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Ikarian Capital's OKUR Position: Q2 2025 in Review

Ikarian Capital sold out of OnKure Therapeutics (OKUR) in Q2 2025, closing a stake of 253,754 shares — an estimated $1.09M sold.

Ikarian Capital first reported a position in OKUR in Q3 2021 and held it in 12 quarters. The position peaked at $2.18M in Q4 2024. 49 funds tracked by Wall St. Rank hold OKUR as of Q2 2025.

Ikarian Capital reported no remaining OnKure Therapeutics position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 253,754 OnKure Therapeutics shares in Q2 2025, an estimated $1.09M.
Ikarian Capital first reported a position in OnKure Therapeutics in Q3 2021 and held it in 12 quarters.
Ikarian Capital's OnKure Therapeutics position peaked at $2.18M in Q4 2024.
49 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.